Select Publications

This page contains recent publications only.


  1. Guenter RE, Aweda T, Carmona Matos DM, Whitt J, Chang AW, Cheng EY, Liu XM, Chen H, Lapi SE, Jaskula-Sztul R. Pulmonary carcinoid surface receptor modulation using histone deacetylase inhibitors. Cancers (Basel). 2019; 11(6): pii: E767.

  2. Carmona-Matos D, Jang S, Hijaz B, Aburjania Z, Cheng A, Lloyd RV, Chen H, Jaskula-Sztul R. Characterization of somatostatin receptors (SSTRs) expression and anti-proliferative effect of somatostatin analogues in aggressive thyroid cancers. Surgery. 2019; 165(1):64-68.

  3. Aburjania Z, Jang S, Whitt J, Jaskula‐Stzul R, Chen H, Rose J. The Role of Notch3 in Cancer. Oncologist. 2018;23(8):900-911.

  4. Lou I, Odorico S, Yu X, Harrison A, Jaskula-Sztul R, Chen H.  Notch3 as a Novel Therapeutic Target in Metastatic Medullary Thyroid Cancer.  Surgery 2018;163(1):104-111.

  5. Rose J, Fields R, Strasberg S. Poor Reproducibility of Gallbladder Ejection Fraction by Biliary Scintigraphy for Diagnosis of Biliary Dyskinesia. Journal of the American College of Surgeons. 2018;226(2):155-159.

  6. Dominguez-Rosado I, Fields R, Woolsey C, Williams G, Horwedel T, Rose J, Hammill C, Doyle M, Chapman W, Strasberg S, Hawkins W, Sanford D. Prospective Evaluation of Pasireotide in Patients Undergoing Pancreaticoduodenectomy: The Washington University Experience. Journal of the American College of Surgeons. 2018;226(2):147-154.e1.

  7. Jaskula–Sztul R, Chen G, Dammalapati A, Harrison A, Tang W, Gong S, Chen H. AB3-loaded and tumor-targeted unimolecular micelles for medullary thyroid cancer treatment. J Mater Chem B. 2017; 5(1):151-159.  PMCID: PMC5180596

  8. Chen G, Jaskula–Sztul R, Esquibel CR, Lou I, Zheng Q, Dammalapati A, Harrison A, Eliceiri KW, Tang W, Chen H, Gong S. Neuroendocrine tumor-targeted upconversion–nanoparticle-based micelles for simultaneous NIR-controlled combination chemotherapy and photodynamic therapy, and fluorescence imaging. Adv Funct Mater. 2017; 27(8):1604671. PMCID: PMC5630134

  9. Jang S, Janssen A, Aburjania Z, Robers MB, Harrison A, Dammalapati A, Cheng YQ, Chen H, Jaskula-Sztul R. Histone deacetylase inhibitor thailandepsin-A activates Notch signaling and suppresses neuroendocrine cancer cell growth in vivo. Oncotarget. 2017; 8(41):70828-70840. PMID: 29050323

  10. Jang S, Jin H, Roy M, Ma AL, Gong S, Jaskula-SztulR, Chen H. Antineoplastic effects of histone deacetylase inhibitors in neuroendocrine cancer cells are mediated through transcriptional regulation of Notch1 by activator protein 1. Cancer Medicine. 2017; 6(9):2142-2152. PMID: 28776955

  11. Jang S, Yu XM, Montemayor-Garcia C, Ahmed K, Weinlander E, Lloyd RV, Dammalapati A, Marshall D, Prudent JR, Chen H. Dysadherin specific drug conjugates for the treatment of thyroid cancers with aggressive phenotypes. Oncotarget. 2017; 11;8(15):24457-24468. PMID: 28160550

  12. Jaskula-Sztul R, Chen G, Dammalapati A, Harrison A, Tang W, Gong S, Chen H. AB3-Loaded and Tumor-Targeted Unimolecular Micelles for Medullary Thyroid Cancer Treatment. J Mater Chem B Mater Biol Med. 2017; 7;5(1):151-159. PMID: 28025618

  13. Somnay YR, Yu XM, Lloyd RV, Leverson G, Aburjania Z, Jang S, Jaskula-Sztul R, Chen H.Notch3 expression correlates with thyroid cancer differentiation, induces apoptosis, and predicts disease prognosis. Cancer. 2017; 1;123(5):769-782. 30403.27861750

  14. Jaskula-Sztul R, Georgen MR, Aburjania Z, Somnay YR, Leverson G, Sippel RS, Lloyd RV, Johnson BP, Chen H. Notch1 signaling regulates the aggressiveness of differentiated thyroid cancer and inhibits SERPINE1 expression. Clinical Cancer Research 2016;22(14):3582-3592.  PMCID: PMC5653217

  15. Somnay Y, Lubner S, Gill H, Matsumura JB, Chen H. ABT-888 potentiates Darbazine-induced cell death in Carcinoids in vitro. Cancer Gene Therapy 2016; 23:348-354. PMID: 27632933 

  16. Golden S, Yu X, Odorico S, Jain V, Marin A, Ma S, Kenney, Chen H. The Epstein-Barr virus EBNA2 protein induces a subset of NOTCH target genes in thyroid cancer cell lines but fails to suppress proliferation. Surgery 2017; 161(1):195-201. PMID: 27847111

  17. Somnay YR, Zarebczan Dull B, Eide J, Jaskula-Sztul R, Chen H. Chrysin suppresses the achaete-scute complex-like1 and alters the neuroendocrine phenotype of carcinoids. Cancer Gene Therapy 2016; 22, 496–505. PMID: 26403073

  18. Yu X, Jaskula-Sztul R, Georgen MR, Aburjania Z, Somnay YR, Leverson G, Sippel RS, Lloyd RV, Johnson BP, Chen H. Notch1 Signaling Regulates the Aggressiveness of Differentiated Thyroid Cancer and Inhibits SERPINE1 Expression. Clinical Cancer Research. 2016; 22: 3582-92

  19. Hardin H, Yu X, Harrison AD, LarrainC, Zhang R, Chen J, Chen H, Lloyd RV. Generation of Novel Thyroid Cancer Stem-Like Cell Clones: Effects of Resveratrol and Valproic Acid. American Journal of Pathology 2016; 186(6):1662-1673. PMID: 27060227

  20. Jaskula-Sztul R, Xu W, Chen G, Harrison A, Dammalapati A, Nair R, Cheng Y, Gong S, Chen H. Thailandepsin A-loaded and octreotide-functionalized unimolecular micelles for targeted neuroendocrine cancer therapy. Biomaterials. 2016; 91: 1-10. PMID: 26994814

For a full list of publications please visit the following links:
Dr. Chen (Pub Med) (UAB Scholar)
Dr. Jaskula-Sztul (Pub Med) (UAB Scholar)
Dr. Rose (Pub Med) (UAB Scholar)